Q: What’s the difference between an SAE and a SUSAR?
It’s one of those distinctions that seems straightforward on paper, but in practice, it requires a lot of real judgment. An SAE, or serious adverse event, is defined by its outcome - death, life-threatening events, hospitalization, and disability. However, it’s important to note that an SAE can be completely expected and unrelated to the drug itself. In oncology, this is almost routine. Patients are already ill, and various things can happen.
A SUSAR, on the other hand, is a much narrower, and more significant, category. It’s not just serious; it’s unexpected and suspected to be related to the investigational product. This combination triggers regulatory urgency. You’re no longer just documenting an event; you’re signaling that something new, potentially unrecognized, is occurring with the drug. That’s when timelines tighten, reporting accelerates, and everyone starts to pay closer attention.
Where this becomes challenging is in the middle ground. A patient develops a known toxicity, but in a way that feels off—earlier onset, different severity, or an atypical presentation. Is it still considered “expected”? Or are you looking at the onset of a new safety signal? This isn’t a simple dictionary exercise. This is where medical monitoring truly comes into play. The difference between labeling something as an SAE versus escalating it as a SUSAR can significantly influence the entire study’s response.
Key takeaway: Every SUSAR is an SAE, but not every SAE is a SUSAR. The difference isn’t just semantic; it signifies whether you’re seeing the established profile of a drug or the first sign that the story is changing.